Lietuva -
lietuvių -
SMCA (Valstybinė vaistų kontrolės tarnyba)
kabergovet 50 mikrogramų/ml, geriamasis tirpalas šunims ir katėms
vet-agro multi-trade company sp. z o.o. (lenkija) - geriamasis tirpalas - kiekviename ml yra: veikliosios medžiagos: kabergolino 50 μg. - kalėms tariamam šuningumui gydyti. kalėms ir katėms laktacijai slopinti.
Lietuva -
lietuvių -
SMCA (Valstybinė vaistų kontrolės tarnyba)
kaltetan forte, 458,4 mg/ml + 125 mg/ml + 20 mg/ml, infuzinis tirpalas arkliams, galvijams ir kiaulėms
vet-agro multi-trade company sp. z o.o. (lenkija) - infuzinis tirpalas - kiekviename mililitre yra: veikliosios (-iųjų) medžiagos (-ų): injekcinio kalcio gliukonato 458,4 mg (atitinka 40,97 mg kalcio arba 1,02 mmol ca2+), magnio chlorido heksahidrato 125 mg (atitinka 14,94 mg magnio arba 0,61 mmol mg2+), natrio glicerofosfato pentahidrato 20 mg (atitinka 2,02 mg fosforo arba 0,07 mmol p5+); - Žinduoliams gydyti esant elektrolitų sutrikimams (kalcio trūkumą dažnai lydi magnio ir fosforo trūkumas): arkliai: klinikinė hipokalcemijos forma. galvijai: klinikinė hipokalcemijos forma, pvz., pieno karštinė (parezė prieš arba po atsivedimo) ir ganyklinė tetanija (klinikinė hipomagnezemijos forma). kiaulės: klinikinė hipokalcemijos forma (parezė prieš arba po atsivedimo).
Lietuva -
lietuvių -
SMCA (Valstybinė vaistų kontrolės tarnyba)
kaltetan, 250 mg/ml + 80 mg/ml + 10 mg/ml, infuzinis tirpalas arkliams, galvijams ir kiaulėms
vet-agro multi-trade company sp. z o.o. (lenkija) - infuzinis tirpalas - kiekviename mililitre yra: veikliosios (-iųjų) medžiagos (-ų): injekcinio kalcio gliukonato 250 mg (atitinka 22,35 mg kalcio arba 0,56 mmol ca2+), magnio chlorido heksahidrato 80 mg (atitinka 9,56 mg magnio arba 0,39 mmol mg2+), natrio glicerofosfato pentahidrato 10 mg (atitinka 1,01 mg fosforo arba 0,03 mmol p5+); - Žinduoliams gydyti esant elektrolitų sutrikimams (kalcio trūkumą dažnai lydi magnio ir fosforo trūkumas): arkliai: klinikinė hipokalcemijos forma. galvijai: klinikinė hipokalcemijos forma, pvz., pieno karštinė (parezė prieš arba po atsivedimo) ir ganyklinė tetanija (klinikinė hipomagnezemijos forma). kiaulės: klinikinė hipokalcemijos forma (parezė prieš arba po atsivedimo).
Europos Sąjunga -
lietuvių -
EMA (European Medicines Agency)
lenalidomide krka d.d. novo mesto (previously lenalidomide krka)
krka, d.d., novo mesto - lenalidomide hydrochloride monohydrate - multiple myeloma; lymphoma, follicular - imunosupresantai - multiple myelomalenalidomide krka d. novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) yra nurodytos gydyti suaugusiems pacientams su anksčiau negydytų mieloma, kurie nėra tinkami persodinti. lenalidomide krka d. novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide krka d. novo mesto in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a). multiple myelomalenalidomide krka d. novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) yra nurodytos gydyti suaugusiems pacientams su anksčiau negydytų mieloma, kurie nėra tinkami persodinti. lenalidomide krka d. novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide krka d. novo mesto in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).
Europos Sąjunga -
lietuvių -
EMA (European Medicines Agency)
lenalidomide krka (previously lenalidomide krka d.d. novo mesto)
krka, d.d., novo mesto - lenalidomide hydrochloride monohydrate - multiple myeloma; myelodysplastic syndromes; lymphoma, follicular; lymphoma, mantle-cell - imunosupresantai - multiple myelomalenalidomide krka as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) yra nurodytos gydyti suaugusiems pacientams su anksčiau negydytų mieloma, kurie nėra tinkami persodinti. lenalidomide krka in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. myelodysplastic syndromeslenalidomide krka as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. mantle cell lymphomalenalidomide krka as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (see sections 4. 4 ir 5. follicular lymphomalenalidomide krka in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a). multiple myelomalenalidomide krka as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) yra nurodytos gydyti suaugusiems pacientams su anksčiau negydytų mieloma, kurie nėra tinkami persodinti. lenalidomide krka in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. myelodysplastic syndromeslenalidomide krka as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. mantle cell lymphomalenalidomide krka as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (see sections 4. 4 ir 5. follicular lymphomalenalidomide krka in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).
Europos Sąjunga -
lietuvių -
EMA (European Medicines Agency)
lenalidomide krka d.d.
krka, d.d., novo mesto - lenalidomide hydrochloride hydrate - multiple myeloma; lymphoma, follicular; myelodysplastic syndromes - imunosupresantai - multiple myelomalenalidomide krka d. as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) yra nurodytos gydyti suaugusiems pacientams su anksčiau negydytų mieloma, kurie nėra tinkami persodinti. lenalidomide krka d. in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. myelodysplastic syndromeslenalidomide krka d. as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. follicular lymphomalenalidomide krka d. in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).
Europos Sąjunga -
lietuvių -
EMA (European Medicines Agency)
zeposia
bristol-myers squibb pharma eeig - ozanimod hidrochloridas - multiple sclerosis, relapsing-remitting; colitis, ulcerative - imunosupresantai - multiple sclerosiszeposia is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (rrms) with active disease as defined by clinical or imaging features. ulcerative colitiszeposia is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.
Lietuva -
lietuvių -
SMCA (Valstybinė vaistų kontrolės tarnyba)
vape super ko2 multi-insect killer
guaber s.r.l., via gramsci, 41-40050, funo (bo) (italija) - cifenotrinas; ?-ciano-3-fenoksibenzil-2,2-dimetil-3-(2-metilprop-1-enil)ciklopropankarboksilatas; cifenotrinas; ?-ciano-3-fenoksibenzil-2,2-dimetil-3-(2-metilprop-1-enil)ciklopropankarboksilatas - veikliosios medžiagos cas nr.: 39515-40-7, eb nr.: 254-484-5, veikliosios medžiagos pavadinimas: cifenotrinas; ?-ciano-3-fenoksibenzil-2,2-dimetil-3-(2-metilprop-1-enil)ciklopropankarboksilatas, koncentracija: 0.3% , veiklioji; veikliosios medžiagos cas nr.: 39515-40-7, eb nr.: 254-484-5, veikliosios medžiagos pavadinimas: cifenotrinas; ?-ciano-3-fenoksibenzil-2,2-dimetil-3-(2-metilprop-1-enil)ciklopropankarboksilatas, koncentracija: 0.3% , veiklioji - insekticidai, akaricidai ir kitų nariuotakojų kontrolės produktai